Dual Role of Caspase 8 in Adipocyte Apoptosis and Metabolic Inflammation.


Journal

Diabetes
ISSN: 1939-327X
Titre abrégé: Diabetes
Pays: United States
ID NLM: 0372763

Informations de publication

Date de publication:
01 Dec 2023
Historique:
received: 18 12 2022
accepted: 29 08 2023
medline: 22 11 2023
pubmed: 13 9 2023
entrez: 12 9 2023
Statut: ppublish

Résumé

Caspases are cysteine-aspartic proteases that were initially discovered to play a role in apoptosis. However, caspase 8, in particular, also has additional nonapoptotic roles, such as in inflammation. Adipocyte cell death and inflammation are hypothesized to be initiating pathogenic factors in type 2 diabetes. Here, we examined the pleiotropic role of caspase 8 in adipocytes and obesity-associated insulin resistance. Caspase 8 expression was increased in adipocytes from mice and humans with obesity and insulin resistance. Treatment of 3T3-L1 adipocytes with caspase 8 inhibitor Z-IETD-FMK decreased both death receptor-mediated signaling and targets of nuclear factor κ-light-chain-enhancer of activated B (NF-κB) signaling. We generated novel adipose tissue and adipocyte-specific caspase 8 knockout mice (aP2Casp8-/- and adipoqCasp8-/-). Both males and females had improved glucose tolerance in the setting of high-fat diet (HFD) feeding. Knockout mice also gained less weight on HFD, with decreased adiposity, adipocyte size, and hepatic steatosis. These mice had decreased adipose tissue inflammation and decreased activation of canonical and noncanonical NF-κB signaling. Furthermore, they demonstrated increased energy expenditure, core body temperature, and UCP1 expression. Adipocyte-specific activation of Ikbkb or housing mice at thermoneutrality attenuated improvements in glucose tolerance. These data demonstrate an important role for caspase 8 in mediating adipocyte cell death and inflammation to regulate glucose and energy homeostasis. Caspase 8 is increased in adipocytes from mice and humans with obesity and insulin resistance. Knockdown of caspase 8 in adipocytes protects mice from glucose intolerance and weight gain on a high-fat diet. Knockdown of caspase 8 decreases Fas signaling, as well as canonical and noncanonical nuclear factor κ-light-chain-enhancer of activated B (NF-κB) signaling in adipose tissue. Improved glucose tolerance occurs via reduced activation of NF-κB signaling and via induction of UCP1 in adipocytes.

Identifiants

pubmed: 37699387
pii: 153599
doi: 10.2337/db22-1033
doi:

Substances chimiques

NF-kappa B 0
Caspase 8 EC 3.4.22.-
Glucose IY9XDZ35W2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1751-1765

Subventions

Organisme : CIHR
ID : ARI-170743
Pays : Canada

Informations de copyright

© 2023 by the American Diabetes Association.

Auteurs

Cynthia T Luk (CT)

Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Toronto, Ontario, Canada.
Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.
Division of Endocrinology and Metabolism, Department of Medicine, St. Michael's Hospital, Unity Health Toronto, Ontario, Canada.
Banting and Best Diabetes Centre, University of Toronto, Toronto, Ontario, Canada.

Carmen K Chan (CK)

Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Toronto, Ontario, Canada.
Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.

Felix Chiu (F)

Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Toronto, Ontario, Canada.

Sally Yu Shi (SY)

Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.
Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada.

Paraish S Misra (PS)

Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Toronto, Ontario, Canada.
Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.

Yu Zhe Li (YZ)

Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada.

Evan Pollock-Tahiri (E)

Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada.

Stephanie A Schroer (SA)

Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada.

Harsh R Desai (HR)

Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada.

Tharini Sivasubramaniyam (T)

Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.
Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada.

Erica P Cai (EP)

Lilly Diabetes Center of Excellence, Indiana Biosciences Research Institute, Indianapolis, IN.
Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN.

Mansa Krishnamurthy (M)

Cincinnati Children's Hospital Medical Center, Cincinnati, OH.

Daniel J Han (DJ)

Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Toronto, Ontario, Canada.
Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.

Apu Chowdhury (A)

Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Toronto, Ontario, Canada.

Rukhsana Aslam (R)

Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Toronto, Ontario, Canada.

Darren A Yuen (DA)

Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Toronto, Ontario, Canada.
Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.

Anne Hakem (A)

University Health Network, Toronto, Ontario, Canada.

Razqallah Hakem (R)

University Health Network, Toronto, Ontario, Canada.

Minna Woo (M)

Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.
Banting and Best Diabetes Centre, University of Toronto, Toronto, Ontario, Canada.
Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada.
Division of Endocrinology, Department of Medicine, University Health Network/Sinai Health System, University of Toronto, Toronto, Ontario, Canada.
University Health Network, Toronto, Ontario, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH